このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Immunovant マネジメント

マネジメント基準チェック /44

Immunovant'sの CEO はPete Salzmannで、 Jun2019年に任命され、の在任期間は 4.67年です。の年間総報酬は$ 5.82Mで、 10.7%給与と89.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.28%を直接所有しており、その価値は$ 11.04M 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と4.7年です。

主要情報

Pete Salzmann

最高経営責任者

US$5.8m

報酬総額

CEO給与比率	10.7%
CEO在任期間	5yrs
CEOの所有権	0.3%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	4.7yrs

経営陣の近況

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

CEO報酬分析

Immunovant の収益と比較して、Pete Salzmann の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$259m
Dec 31 2023	n/a	n/a	-US$243m
Sep 30 2023	n/a	n/a	-US$255m
Jun 30 2023	n/a	n/a	-US$245m
Mar 31 2023	US$6m	US$625k	-US$211m
Dec 31 2022	n/a	n/a	-US$199m
Sep 30 2022	n/a	n/a	-US$177m
Jun 30 2022	n/a	n/a	-US$167m
Mar 31 2022	US$6m	US$600k	-US$157m
Dec 31 2021	n/a	n/a	-US$138m
Sep 30 2021	n/a	n/a	-US$128m
Jun 30 2021	n/a	n/a	-US$111m
Mar 31 2021	US$15m	US$567k	-US$107m
Dec 31 2020	n/a	n/a	-US$100m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	US$9m	US$361k	-US$66m

報酬と市場: Peteの総報酬 ($USD 5.82M ) は、 US市場 ($USD 6.83M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Peteの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Pete Salzmann (56 yo)

5yrs

在職期間

US$5,819,818

報酬

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer of Immunovant, Inc. since June 2019 and has been its Director since October 2019. Dr. Salzmann is an Independent Director...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frank Torti	Executive Chairperson of the Board	5yrs	US$2.49m	0.082% $ 3.2m
Peter Salzmann	CEO & Director	5yrs	US$5.82m	0.28% $ 11.0m
Eva Barnett	Chief Financial Officer	2.7yrs	US$2.07m	0.081% $ 3.2m
William Macias	Chief Medical Officer	3yrs	US$1.92m	0.13% $ 5.0m
Jay Stout	Chief Technology Officer	1.2yrs	データなし	データなし
Chau Cheng	Vice President of Investor Relations	1.8yrs	データなし	データなし
Mark Levine	Chief Legal Officer & Corporate Secretary	2.4yrs	データなし	0.064% $ 2.5m
Lauren Schrier	Vice President of Marketing	4.4yrs	データなし	データなし
Christine Blodgett	Vice President of Human Resources	no data	データなし	データなし
Julia Butchko	Chief Development Officer	1.2yrs	US$7.84m	0.17% $ 6.5m
Andy Deig	Vice President of Financial Planning & Chief of Staff to the CEO	no data	データなし	データなし
Michael Geffner	Chief Medical Officer	no data	データなし	0.012% $ 479.5k

2.7yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: IMVTの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Frank Torti	Executive Chairperson of the Board	5yrs	US$2.49m	0.082% $ 3.2m
Peter Salzmann	CEO & Director	4.7yrs	US$5.82m	0.28% $ 11.0m
George Migausky	Independent Director	4.5yrs	US$291.32k	0.0098% $ 383.2k
Andrew Fromkin	Director	4.7yrs	US$298.82k	データなし
Atul Pande	Independent Director	4.7yrs	US$287.62k	0.014% $ 535.9k
Douglas Hughes	Independent Director	4.7yrs	US$290.12k	0.012% $ 488.9k
Eric Venker	Director	4.3yrs	データなし	データなし

4.7yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: IMVTの取締役会は経験豊富であると考えられます ( 4.7年の平均在任期間)。

Immunovant マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

CEO & Director recently sold US$486k worth of stock

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

CEO & Director recently sold US$532k worth of stock

Recent updates

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Price target decreased to US$10.78

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Price target decreased to US$11.25

Chief Medical Officer recently sold US$222k worth of stock

Price target decreased to US$12.25

Immunovant, Inc. Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Independent Director recently bought US$150k worth of stock

Independent Director recently bought US$54k worth of stock

Price target decreased to US$19.86

Immunovant, Inc. announced that it has received $199.999993 million in funding

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth-Defensive Index

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Price target decreased to US$31.88

Immunovant EPS beats by $0.04

The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New 90-day low: US$15.94

Pomerantz Law Firm Announces Filing of Class Action Against Immunovant, Inc

New 90-day low: US$24.10

Price target lowered to US$43.00

マネジメント基準チェック /44